Physiomics (PYC) Competitors GBX 0.45 -0.03 (-6.25%) As of 10:24 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsBuy This Stock PYC vs. TCF, EVG, MTFB, ROQ, BSFA, DEST, NFX, VAL, RENE, and SALVShould you be buying Physiomics stock or one of its competitors? The main competitors of Physiomics include Theracryf (TCF), Evgen Pharma (EVG), Motif Bio (MTFB), Roquefort Therapeutics (ROQ), BSF Enterprise (BSFA), Destiny Pharma (DEST), Nuformix (NFX), ValiRx (VAL), ReNeuron Group (RENE), and SalvaRx Group (SALV). These companies are all part of the "biotechnology" industry. Physiomics vs. Its Competitors Theracryf Evgen Pharma Motif Bio Roquefort Therapeutics BSF Enterprise Destiny Pharma Nuformix ValiRx ReNeuron Group SalvaRx Group Theracryf (LON:TCF) and Physiomics (LON:PYC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment. Does the media refer more to TCF or PYC? In the previous week, Physiomics had 1 more articles in the media than Theracryf. MarketBeat recorded 1 mentions for Physiomics and 0 mentions for Theracryf. Theracryf's average media sentiment score of 0.00 beat Physiomics' score of -0.65 indicating that Theracryf is being referred to more favorably in the media. Company Overall Sentiment Theracryf Neutral Physiomics Negative Which has preferable earnings and valuation, TCF or PYC? Physiomics has higher revenue and earnings than Theracryf. Physiomics is trading at a lower price-to-earnings ratio than Theracryf, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTheracryfN/AN/A-£5.45M-£0.00-57.78Physiomics£784.01K1.74-£922.82K-£0.00-264.71 Which has more volatility & risk, TCF or PYC? Theracryf has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, Physiomics has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500. Do insiders and institutionals have more ownership in TCF or PYC? 7.8% of Theracryf shares are held by institutional investors. Comparatively, 2.9% of Physiomics shares are held by institutional investors. 22.7% of Theracryf shares are held by company insiders. Comparatively, 4.9% of Physiomics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is TCF or PYC more profitable? Physiomics has a net margin of -106.80% compared to Theracryf's net margin of -792.17%. Theracryf's return on equity of -99.97% beat Physiomics' return on equity.Company Net Margins Return on Equity Return on Assets Theracryf-792.17% -99.97% -48.26% Physiomics -106.80%-127.68%-76.38% SummaryTheracryf and Physiomics tied by winning 6 of the 12 factors compared between the two stocks. Get Physiomics News Delivered to You Automatically Sign up to receive the latest news and ratings for PYC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PYC vs. The Competition Export to ExcelMetricPhysiomicsBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£1.36M£232.15M£6.13B£2.60BDividend Yield6.20%3.80%5.66%5.29%P/E Ratio-264.7194.6985.974,463.41Price / Sales1.746,100.35531.4999,579.86Price / Cash4.2113.1926.3027.90Price / Book2.16110.2112.728.18Net Income-£922.82K-£90.99M£3.30B£5.89B7 Day PerformanceN/A5.16%4.30%1.01%1 Month Performance5.63%8.11%7.58%6.25%1 Year Performance-35.71%621.09%73.65%155.29% Physiomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PYCPhysiomicsN/AGBX 0.45-6.3%N/A-31.4%£1.36M£784.01K-264.7110Earnings ReportGap DownTCFTheracryfN/AGBX 0.23+7.0%N/A-68.8%£4.94MN/A-63.8910Gap UpHigh Trading VolumeEVGEvgen PharmaN/AN/AN/AN/A£3.42MN/A-80.0010MTFBMotif BioN/AN/AN/AN/A£3.28MN/A-0.036ROQRoquefort TherapeuticsN/AGBX 2.08-5.7%N/A-43.7%£3.27MN/A-276.679Earnings ReportHigh Trading VolumeBSFABSF EnterpriseN/AGBX 2.57+0.6%N/A-26.6%£3.17M£24.09K-180.6312Gap UpDESTDestiny PharmaN/AN/AN/AN/A£2.87M£135.03K-50.0024Gap DownHigh Trading VolumeNFXNuformix1.301 of 5 starsGBX 0.15+13.1%GBX 293+199,219.7%+336.4%£2.49MN/A-36.753Gap UpHigh Trading VolumeVALValiRxN/AGBX 0.60-4.0%N/A-60.1%£2.25M£49.78K-41.385,450Earnings ReportRENEReNeuron GroupN/AN/AN/AN/A£1.93M£783K-37.502Gap DownSALVSalvaRx GroupN/AN/AN/AN/A£1.65M£64.50M0.032Gap Up Related Companies and Tools Related Companies Theracryf Competitors Evgen Pharma Competitors Motif Bio Competitors Roquefort Therapeutics Competitors BSF Enterprise Competitors Destiny Pharma Competitors Nuformix Competitors ValiRx Competitors ReNeuron Group Competitors SalvaRx Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:PYC) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored"I'm risking my reputation on this"My prediction: Q4 2025 won't just be another seasonal crypto pump. It will be the quarter that sparks a crypto...Crypto 101 Media | SponsoredWall Street legend: “Sell this A.I. stock now”Whats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.Chaikin Analytics | SponsoredThe next wave of AI fortunes may come from NVIDIA’s secret supplier.Bloomberg says AI is a $50 trillion revolution. And at the center of it… isn't NVIDIA. It's a tiny suppl...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Physiomics Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Physiomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
